CN103974944B - 用作kv3抑制剂的乙内酰脲衍生物 - Google Patents
用作kv3抑制剂的乙内酰脲衍生物 Download PDFInfo
- Publication number
- CN103974944B CN103974944B CN201280059633.9A CN201280059633A CN103974944B CN 103974944 B CN103974944 B CN 103974944B CN 201280059633 A CN201280059633 A CN 201280059633A CN 103974944 B CN103974944 B CN 103974944B
- Authority
- CN
- China
- Prior art keywords
- disorder
- ethyl acetate
- disorders
- benzofuran
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OZVVXTIUZOQWQZ-UHFFFAOYSA-N CC(COc(cccc1OC(C)=O)c1Br)=C Chemical compound CC(COc(cccc1OC(C)=O)c1Br)=C OZVVXTIUZOQWQZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2011/052414 WO2012076877A1 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
| GBPCT/GB2011/052414 | 2011-12-06 | ||
| PCT/GB2012/053045 WO2013083994A1 (en) | 2011-12-06 | 2012-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103974944A CN103974944A (zh) | 2014-08-06 |
| CN103974944B true CN103974944B (zh) | 2016-11-02 |
Family
ID=47429936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280059633.9A Active CN103974944B (zh) | 2011-12-06 | 2012-12-06 | 用作kv3抑制剂的乙内酰脲衍生物 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2788339B1 (enExample) |
| JP (1) | JP5985651B2 (enExample) |
| KR (1) | KR20140098850A (enExample) |
| CN (1) | CN103974944B (enExample) |
| AU (1) | AU2012349847B2 (enExample) |
| CA (1) | CA2856654C (enExample) |
| DK (1) | DK2788339T3 (enExample) |
| ES (1) | ES2576628T3 (enExample) |
| IL (2) | IL232612B (enExample) |
| IN (1) | IN2014CN04014A (enExample) |
| MX (1) | MX356813B (enExample) |
| PL (1) | PL2788339T3 (enExample) |
| WO (1) | WO2013083994A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2718285B1 (en) | 2011-06-07 | 2016-03-16 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| CN104334547B (zh) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| BR112014028718A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | derivados de hidantoína como inibidores de kv3 |
| WO2013182851A1 (en) * | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| WO2018220762A1 (ja) | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| CA3110251A1 (en) * | 2018-09-21 | 2019-11-28 | Bionomics Limited | Substituted-pyridinyl compounds and uses thereof |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| FI3867247T3 (fi) * | 2018-10-16 | 2024-10-30 | Autifony Therapeutics Ltd | Uusia yhdisteitä |
| SG11202104374WA (en) * | 2018-11-30 | 2021-05-28 | Otsuka Pharma Co Ltd | Heterocyclic compounds for the treatment of epilepsy |
| BR112022013339A2 (pt) * | 2020-02-06 | 2022-09-13 | Autifony Therapeutics Ltd | Moduladores de kv3 |
| WO2023017263A1 (en) | 2021-08-10 | 2023-02-16 | Autifony Therapeutics Limited | Potassium channel modulators |
| EP4630117A1 (en) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
| CN117448440B (zh) * | 2023-10-23 | 2024-11-01 | 中国人民解放军空军军医大学 | Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675403A (en) * | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
| CN1134149A (zh) * | 1993-11-01 | 1996-10-23 | H.伦德贝克公司 | 苯基吲哚化合物 |
| WO2011069951A1 (en) * | 2009-12-11 | 2011-06-16 | Glaxo Group Limited | Imidazolidinedione derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG172778A1 (en) * | 2008-12-22 | 2011-08-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| WO2011073114A1 (en) * | 2009-12-14 | 2011-06-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2012076877A1 (en) * | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| EP2718285B1 (en) * | 2011-06-07 | 2016-03-16 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
-
2012
- 2012-12-06 CA CA2856654A patent/CA2856654C/en active Active
- 2012-12-06 KR KR1020147018643A patent/KR20140098850A/ko not_active Ceased
- 2012-12-06 DK DK12806092.8T patent/DK2788339T3/en active
- 2012-12-06 ES ES12806092.8T patent/ES2576628T3/es active Active
- 2012-12-06 PL PL12806092.8T patent/PL2788339T3/pl unknown
- 2012-12-06 JP JP2014545355A patent/JP5985651B2/ja active Active
- 2012-12-06 EP EP12806092.8A patent/EP2788339B1/en active Active
- 2012-12-06 AU AU2012349847A patent/AU2012349847B2/en active Active
- 2012-12-06 WO PCT/GB2012/053045 patent/WO2013083994A1/en not_active Ceased
- 2012-12-06 CN CN201280059633.9A patent/CN103974944B/zh active Active
- 2012-12-06 IN IN4014CHN2014 patent/IN2014CN04014A/en unknown
- 2012-12-06 MX MX2014006753A patent/MX356813B/es active IP Right Grant
-
2014
- 2014-05-14 IL IL232612A patent/IL232612B/en active IP Right Grant
-
2018
- 2018-04-15 IL IL258704A patent/IL258704B/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675403A (en) * | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
| CN1134149A (zh) * | 1993-11-01 | 1996-10-23 | H.伦德贝克公司 | 苯基吲哚化合物 |
| WO2011069951A1 (en) * | 2009-12-11 | 2011-06-16 | Glaxo Group Limited | Imidazolidinedione derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2856654C (en) | 2020-03-31 |
| AU2012349847A1 (en) | 2014-06-26 |
| MX2014006753A (es) | 2014-10-15 |
| KR20140098850A (ko) | 2014-08-08 |
| IL258704B (en) | 2019-05-30 |
| IL232612B (en) | 2018-07-31 |
| HK1203072A1 (zh) | 2015-10-16 |
| IN2014CN04014A (enExample) | 2015-07-10 |
| JP5985651B2 (ja) | 2016-09-06 |
| IL258704A (en) | 2018-06-28 |
| EP2788339B1 (en) | 2016-03-09 |
| EP2788339A1 (en) | 2014-10-15 |
| CN103974944A (zh) | 2014-08-06 |
| IL232612A0 (en) | 2014-06-30 |
| JP2015502951A (ja) | 2015-01-29 |
| CA2856654A1 (en) | 2013-06-13 |
| AU2012349847B2 (en) | 2017-02-16 |
| DK2788339T3 (en) | 2016-05-23 |
| WO2013083994A1 (en) | 2013-06-13 |
| ES2576628T3 (es) | 2016-07-08 |
| PL2788339T3 (pl) | 2016-09-30 |
| MX356813B (es) | 2018-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103974944B (zh) | 用作kv3抑制剂的乙内酰脲衍生物 | |
| US11541052B2 (en) | Compounds | |
| CN103596943B (zh) | 用作kv3抑制剂的乙内酰脲衍生物 | |
| JP5788404B2 (ja) | イミダゾリジンジオン誘導体 | |
| CN104334547B (zh) | 作为kv3抑制剂的三唑类 | |
| TWI827706B (zh) | 新穎化合物 | |
| HK1203072B (en) | Hydantoin derivatives useful as kv3 inhibitors | |
| BR112014013400B1 (pt) | Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil | |
| HK40081003B (zh) | Kv3调节剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |